Finally, an increasing number of publications support a role for aberrant MALT1 signaling in the development of non-lymphoid cancers, such as glioblastoma (127), breast cancer (18, 128, 129), melanoma (130), lung cancer (18), and various other carcinomas (1, 131, 132). This evidence concerns the gene MALT1 and lung carcinoma.